Two Low Volume Regimens for Colorectal Cancer Screening Colonoscopy

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

1002 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-03-11

Study Completion Date

2022-06-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Colorectal cancer is the first neoplasm most commonly diagnosed in both sexes and the second leading cause of cancer death in Spain. Colorectal cancer screening Program in Barcelona was implanted in 2009 and approximately 1,500 colorectal cancer screening colonoscopies are performed annually at Hospital Clínic de Barcelona. Adequate colon preparation (anterograde cleansing with laxatives) improves polyp detection, decreases examination time, and complications. There are both low and high volume intestinal regimens with polyethylene glycol (PEG) as the main active ingredient or without it.

Hypothesis: Two low volumen regimens, 1L PEG plus ascorbate and magnesium citrate plus picosulphate, at starting doses have the same Adenoma Detection Rate as cleansing solutions in preparation for screening colonoscopy.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Early Diagnosis of Colorectal Cancer Based on a Non-invasive Metabolomics Profile

NCT06452745

Colorectal Cancer Colorectal Adenoma Colorectal Polyp +1 more

RECRUITING

Colorectal Cancer: Screening vs. Non-Screening

NCT02727894

Colorectal Cancer Screening

COMPLETED

Comparative Study of Colon Capsule and Virtual Colonoscopy (VICOCA)

NCT02081742

Colonic Polyps Adenoma

COMPLETED

Usefulness of Chromoendoscopy for the Early Detection of Colorectal Cancer Associated With Inflammatory Bowel Disease

NCT02543762

Inflammatory Bowel Disease Colorectal Cancer

COMPLETED

Endoscopic Versus Surgical Treatment for T1 Colorectal Cancer

NCT04150081

Colorectal Cancer

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The primary objective of the study is to compare the clinical efficacy (by comparing the adenoma detection rate) of 1L PEG plus ascorbate versus magnesium citrate plus picosulphate in subjects undergoing colonoscopy in a colorectal cancer screening programme. We also will compare the Lesion Detection Rate, the quality of colon cleansing (Boston classification) overall and by segments, the tolerability and satisfaction and the rate of adverse effects experienced with intake of these products.

Methodology: A comparative, parallel, randomized, single-centre, low-intervention clinical trial to be conducted at the CCR screening unit of Hospital Clínic de Barcelona that will include 1,002 participants.

Subjects will complete a Tolerability and Satisfaction Questionnaire after completing the bowel preparation. Findings (polyps, CRC, or other lesions) and quality of bowel cleansing will be collected from the colonoscopy report.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Colorectal Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

A comparative, parallel, randomized, non-inferiority, non-blinded, single-centre and low-intervention clinical trial

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Plenvu

Plenvu split dose

Group Type EXPERIMENTAL

Plenvu

Intervention Type DRUG

randomization 1:1

Citrafleet

citrafleet in split dose

Group Type ACTIVE_COMPARATOR

Plenvu

Intervention Type DRUG

randomization 1:1

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Plenvu

randomization 1:1

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

citrafleet

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Men and women aged 50 to 69 years who have participated in the early detection programme for colon and rectal cancer (PDPCCR) in Barcelona, who have obtained a positive result in the faecal occult blood test (≥20 μg Hb/g faeces) and who are scheduled for a screening colonoscopy at Hospital Clínic de Barcelona.

Exclusion Criteria

* People who do not agree to participate in the study.
* People with known severe renal failure (grade IV or V) and grade III and IV heart failure according to the New York Heart Association (NYHA) Scale of Functional Assessment of Heart Failure
* Individuals who have undergone a colonoscopy in the past year.
* Subjects meeting the Rome IV Criteria for the diagnosis of functional constipation
* Subjects with mental disabilities or with a severe mental disorder (schizophrenia and other psychotic disorders, recurrent severe major depressive disorders, severe obsessive-compulsive disorder, severe personality disorders and bipolar disorders).
* Individuals who do not understand Catalan or Spanish verbally and in writing.
* Individuals with partial or total colon resection.
* Individuals with a personal history of CRC or colorectal disease amenable to specific follow-up (ulcerative colitis, Crohn's disease, or colorectal adenomas).
* Individuals with terminal illness or severe illness/disability that contraindicates further study of the colon.
* People with gastrointestinal disorders that contraindicate the use of the study products (gastric emptying disorders, perforation or gastrointestinal obstruction, ileus, toxic megacolon).
* People with congestive heart failure
* Hypermagnesemia
* Rhabdomyolysis
* Phenylketourine
* Glucose-6-phosphate dehydrogenase deficiency
* People with hypersensitivity to the active ingredients of excipients
* People with severe renal impairment

Minimum Eligible Age

50 Years

Maximum Eligible Age

69 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No